Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA
In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty today to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy's manufacturing facilities in India, the Justice Department announced today. Ranbaxy also agreed to pay a criminal fine and forfeiture totaling $150 million and to settle civil claims under the False Claims Act and related State laws for $350 million.
- Date:May 13, 2013
- Agency:U.S. Department of Justice
- Criminal and Civil Actions